



FOR IMMEDIATE RELEASE

CMD BIOSCIENCE ANNOUNCED TODAY IT IS PRESENTING AT THE ROCHE COLORADO CORPORATION PEPTIDE SYMPOSIUM 2011 IN BOULDER COLORADO.

New Haven, CT September 8th , 2011: CMDBioscience announced today that they will present at the Roche Colorado Corporation Peptide Symposium 2011 in Boulder Colorado. The company will present recent case studies related to CMDInventusSM, their proprietary computational discovery platform aimed at discovering novel peptide candidates in the Peptide Technology Showcase.

CMDInventusSM offers pharmaceutical, biotech and life science companies a ground breaking tool to assist with their peptide discovery projects. CMDInventusSM has been fully validated by multiple research projects, including a project aimed at identifying novel dengue virus anti-infective agents. CMDBioscience scientists used CMDInventusSM to interrogate a key dengue viral protein structural motif and rationally design small peptides that bound to the motif. The project, completed in seven weeks time, involved the explicit consideration of 480,000 peptide sequences and ultimately converged on the 27 most promising peptides. Subsequent synthesis and experimental testing revealed excellent anti-infective activity for 5 of the designed peptides.

"We are very pleased to participate in RCCPS 2011. By participating in the Peptide Showcase on September 13th, we progress the product launch of CMDInventusSM, our proprietary peptide discovery and computational platform. In particular, we intend to highlight CMDInventusSM our business model, and how partner companies can significantly reduce the discovery time associated with identifying novel peptides by taking advantage of this innovative technology." Said Mark Jarosinski, PhD, Director of Business Development for CMDBioscience.

"Our participation allows us to reach scientific and business leadership from both Pharmaceutical and Biotechnology industries that are focused on discovery and development of peptide-based therapeutics. We will discuss the value of CMDInventusSM and detail specific milestone results we generated for both an internal discovery project and novel projects of partner organizations." Said Mark Jarosinski. "We are confident that CMDInventusSM is a novel enabling technology in the field of peptide discovery, and intend to highlight that at this year's conference".

About: CMDBioscience is a computational biotechnology company that specializes in the computer-enabled analysis, modeling and design of therapeutic protein-peptide interactions or structure-based peptide design. Using our proprietary discovery platform CMDInventusSM, CMD scientists can help partner organizations efficiently identify novel peptide hits and leads, understand the structural basis of protein-peptide interactions, and rationally optimize peptide leads.

CMD Bioscience contact:

www.cmdbioscience.com

Mark Jarosinski, PhD

Director, Business Development

mark.jarosinski@cmdbioscience.com

Phone 317-313-9713